03.03.2022 - Medicenna’s Clinical Advisory Board is comprised of thought leaders in immuno-oncology with experience in clinical development of Proleukin and next generation IL-2 Dr. Dhingra has a track record of development and approval of cancer therapies and . Seite 1
Medicenna Announces Peer-Reviewed Publication of Preclinical Data on MDNA11 in the Journal for ImmunoTherapy of Cancer MDNA11 demonstrates a 30-fold increase in affinity for. | January 26, 2022
Peak CD8+ T cell / Treg ratio increased ~2-3 fold over baseline with MDNA11 treatment in the trial’s first two dose escalation cohorts MDNA11-induced increases in CD8+ T and NK. | December 22, 2021
Peak CD8+ T cell / Treg ratio increased ~2-3 fold over baseline with MDNA11 treatment in the trial’s first two dose escalation cohorts MDNA11-induced increases in CD8+ T and NK cells. | December 22, 2021
17.12.2021 - - ABILITY Study is currently ongoing at clinical trial sites in Australia and previously received FDA clearance to expand to sites in the United States - Preliminary update on safety and PK/PD data expected by year-end 2021 - Initial efficacy data . Seite 1